Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Usmani, Saad
One or more keywords matched the following items that are connected to Usmani, Saad
Item TypeName
Concept B-Cell Maturation Antigen
Academic Article Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Academic Article Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma.
Academic Article Teclistamab, a B-cell maturation antigen???CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Academic Article BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
Academic Article Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Academic Article Teclistamab in Relapsed or Refractory Multiple Myeloma.
Academic Article GPRC5D-Targeted CAR T Cells for Myeloma.
Academic Article Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Academic Article Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.
Academic Article CD8 effector T cells enhance teclistamab response in BCMA-exposed and -na?ve multiple myeloma.
Academic Article Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy.
Academic Article Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
Academic Article Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Academic Article Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Academic Article Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.
Academic Article CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53.
Search Criteria
  • B Cell Maturation Antigen